Founded by world-class scientists, clinicians, engineers, and operators, our companies, Panacea Capital companies tackle some of the hardest problems in modern biomedical science — with precision, pace, and global ambition.
OutSee
OutSee applies an AI driven “genetics-first” approach, which diverges from traditional methods, by identifying disease-modulating mechanisms directly from genomic data. By identifying functional disruptions at the molecular level, OutSee suggests novel, genetically validated therapeutic targets, improving treatment success rates and trial outcomes
https://outsee.co.uk/
MitoRx Therapeutics
MitoRx Therapeutics' first-in-class first-in-mechanism mitochondriotropic platform has the potential to address some of the most challenging diseases, focusing initially on cardiometabolic indications and myopathies, and expandable to broad additional areas of medicine.
https://www.mitorxtherapeutics.com/
Axiom Therapeutics
Axiom Therapeutics applies physics enabled AI to design the next generation of covalent drugs for previously undruggable targets. These permanently bonded drugs may offer increased potency and specificity while reducing dose-limiting toxicity and off-target effects.
https://www.axiom-therapeutics.com/
CardiaTec
CardiaTec is a TechBio company leveraging large scale multiomics data to discover novel cardiovascular therapeutics. Spun out of the Han Lab, University of Cambridge, CardiaTec is building the largest human cardiac tissue multiomic database with first targets ready for pre-clinical validation.
https://cardiatec.ai/
Ignota Labs
Ignota Labs rescues promising drugs from failure, through a proprietary AI model, SAFEPATH, applying deep learning to combined bioinformatics and cheminformatics datasets to solve drug safety issues. Bringing new life to abandoned projects and new hope to patients.
https://www.ignotalabs.ai/
